Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,956.00
(
0.71%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
95.52
(
0.54%
)
Bitcoin
77,984.23
(
2.17%
)
News Focus
News Focus
Post# of 517475
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 147
Posts 26188
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: frrol post# 381493

Thursday, 11/03/2022 7:31:32 PM

Thursday, November 03, 2022 7:31:32 PM

Post# of 517475
frrol: I agree with the following:

We'll likely be getting important color on the AD TLR. An overall reduction in % cognitive and functional decline will be crucial to compare to Lecanemab, but stratification on our pre-defined cohorts - dose, S1 and APOE status, and cognitive baseline - will be of great interest at CTAD. And regulators. It's where precision medicine meets the road and hopefully there are some good correlation coeffs.



GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News